Polymorphisms in Plasmodium falciparum Kelch 13 and P. vivax Kelch 12 Genes in Parasites Collected from Three South Pacific Countries Prior to Extensive Exposure to Artemisinin Combination Therapies-Reference-Cited by-同舟云学术

Polymorphisms in Plasmodium falciparum Kelch 13 and P. vivax Kelch 12 Genes in Parasites Collected from Three South Pacific Countries Prior to Extensive Exposure to Artemisinin Combination Therapies

Published:2019-07 Issue:7 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Gresty Karryn¹²,Anderson Karen¹²,Pasay Cielo¹³,Waters Norman C.⁴,Cheng Qin¹²

Affiliation:

1. Drug Resistance and Diagnostic Department, Australian Defence Force Malaria and Infectious Disease Institute, Brisbane, Australia

2. The Army Malaria Institute Laboratory, QIMR-Berghofer Medical Research Institute, Brisbane, Australia

3. Clinical Tropical Medicine, QIMR-Berghofer Medical Research Institute, Brisbane, Australia

4. Walter Reed Army Institute of Research, Silver Spring, Maryland, USA

Abstract

The South Pacific countries Solomon Islands, Vanuatu, and Papua New Guinea (PNG) adopted artemisinin-based combination therapies (ACTs) in 2008. We examined Kelch 13 and Kelch 12 genes in parasites originating from these countries before or at ACT introduction.

Funder

DOD | Defense Health Agency

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00536-19

Reference58 articles.

1. WHO. 2018. World malaria report 2018. World Health Organization, Geneva, Switzerland.

2. WHO. 2006. Guidelines for the treatment of malaria. World Health Organization, Geneva, Switzerland.

3. Evidence of Artemisinin-Resistant Malaria in Western Cambodia